March 31, 2022 | Cogstate, Decentralized trials, Impetus Digital, Natalie Yeadon, Pam Ventola, brain health, central rating, central scoring, clinical insights, clinical trials, cognitive testing, digital assessments, rare disease
Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can help advance the development of new medicines and enable earlier clinical insights. She also discusses cognitive testing as part of decentralized trials, the role of central rating and central scoring, the development of indication-specific COAs for rare disease trials, and much more.
This content was provided by Impetus Digital
Company Details
